Mid-Term Outcomes of Endovascular Treatment for TASC-II D @entity432 with XXXX .

@entity1 @entity63 @entity75 @entity256 @entity432
PURPOSE: The purpose of the study was to assess the safety and midterm effectiveness of endovascular treatment in Trans-Atlantic Inter-Society Consensus II (TASC-II) D femoropopliteal occlusions in @entity1 with @entity63 ( @entity63 ). METHODS: @entity1 with @entity63 who underwent endovascular treatment for TASC-D de novo femoropopliteal occlusive disease between September 2008 and December 2013 were selected. Data included anatomic features, pre- and postprocedure ankle-brachial index, duplex ultrasound, and periprocedural complications. Sustained clinical improvement, limb salvage rate, freedom from @entity75 revascularization (TLR), and freedom from target extremity revascularization (TER) were assessed by Kaplan-Meier estimation and predictors of @entity256 / @entity432 with Cox analysis. RESULTS: Thirty-two @entity1 underwent treatment of 35 TASC-D occlusions. Mean age was 76    9. Mean lesion length was 23    5 cm. Twenty-eight limbs (80 %) presented tissue loss. Seventeen limbs underwent treatment by stent, 13 by stent-graft, and 5 by angioplasty. Mean follow-up was 29    20 months. Seven @entity1 required major amputation and six @entity1 died during follow-up. Eighteen endovascular and three surgical TLR procedures were performed due to @entity256 or @entity432 . Estimated freedom from TLR and TER rates at 2 years were 41 and 76%, whereas estimated primary and secondary patency rates were 41 and 79%, respectively. CONCLUSIONS: Endovascular treatment for TASC II D lesions is safe and offers satisfying outcomes. This @entity1 subset would benefit from a minimally invasive approach. Follow-up is advisable due to a high rate of @entity256 . Further follow-up is necessary to know the long-term efficacy of these procedures.
